ReCode Therapeutics Reports Initial Dosing of Subjects in Phase 1 Trial for Inhaled mRNA Therapy, RCT2100, Aimed at Cystic Fibrosis Treatment.

Aleta Biotherapeutics and Cancer Research UK’s Centre for Drug Development has initiated dosing in the early-stage ALETA-001 clinical study, targeting individuals with recurrent or unresponsive B-cell cancers.

FDA has sanctioned a biweekly administration of TECVAYLI® (teclistamab-cqyv) as a therapeutic option for those suffering from recurring or unresponsive multiple myeloma.

The experimental biosimilar by Polpharma Biologics demonstrates similar pharmacokinetics and dynamics to the top-selling IBD medication, Entyvio®.

Voyager Therapeutics Announces Promising Early-Stage Results for Gene Therapy Aimed at Attenuating Tau in Alzheimer's, Pushes Project into Later Research Phase.

Immune-Onc Therapeutics Discloses a Partnership for Clinical Research, Assessing IO-108 in an International Early Phase Trial Aimed at Initial Therapy for Progressive Hepatic Carcinoma.

Monopar Approved to Initiate Initial Human Stage 1 Study of Experimental Radiotherapeutic MNPR-101-Zr for Progressive Cancer Cases.

The FDA has granted Mabwell authorization to proceed with their new ADC targeting B7-H3, referred to as 7MW3711 under an Investigational New Drug application.

Iterion Therapeutics stated that initial dosing has commenced in an early to mid-stage study of their drug Tegavivint for advanced liver cancer cases unresponsive to previous systemic therapies.

Teva Pharmaceuticals has released encouraging initial results concerning the safety, patient tolerance, and pharmacokinetic profile of its investigational product known as anti-TL1A (TEV-’574).

NextPoint Therapeutics Reveals Initiation of Early-Stage Clinical Study with First Subject Receiving NPX887 for Solid Tumors Containing HHLA2, an Innovative Treatment Aiming to Revitalize Worn-Out T and NK Cells.

argenx has reported that the FDA has granted priority review status for their updated biologics application for VYVGART Hytrulo, aimed at treating chronic inflammatory demyelinating polyneuropathy.